Aplastic Anemia Market Report 2026

The aplastic anemia market size has grown strongly in recent years. It will grow from $7.01 billion in 2025 to $7.43 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increased clinical awareness of rare hematological disorders, availability of immunosuppressive drug therapies, establishment of bone marrow transplant centers, improved diagnostic capabilities, growth of hospital-based treatment infrastructure.

The aplastic anemia market size is expected to see strong growth in the next few years. It will grow to $9.08 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to advancements in regenerative medicine, rising adoption of personalized hematology treatments, increasing investment in rare disease research, expansion of stem cell donor registries, development of novel immunomodulatory drugs. Major trends in the forecast period include increasing adoption of targeted immunosuppressive therapies, growing use of stem cell and bone marrow transplantation, rising focus on early and accurate diagnosis, expansion of personalized treatment protocols, improved supportive care management.

The increasing demand for personalized medicines is anticipated to drive the growth of the aplastic anemia market in the coming years. Personalized medicine involves customizing medical treatment to the unique characteristics of each patient, often utilizing genetic or molecular profiling. This growing demand is fueled by advancements in genetic testing and molecular diagnostics. In the context of aplastic anemia, personalized medicine entails treatments tailored to the genetic and molecular profiles of patients to enhance outcomes. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, up from six approvals in 2022. Consequently, the rising demand for personalized medicines is contributing to the expansion of the aplastic anemia market.

Major companies operating in the aplastic anemia market are concentrating on developing advanced cell therapy solutions, such as nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, to improve treatment efficacy and patient outcomes. Nicotinamide-modified cell therapy utilizes the properties of nicotinamide to expand and enhance cells, generating allogeneic cell therapy products that have the potential to be curative for patients with hematologic disorders. For example, in August 2025, Ayrmid Ltd., a UK-based cell therapy company, announced FDA acceptance and priority review for omidubicel for the treatment of severe aplastic anemia with a PDUFA. Omidubicel, derived from umbilical cord blood, contains nicotinamide-modified cells that enhance hematopoietic progenitor cell function. The therapy aims to offer a potentially curative option for patients without a matched sibling donor and to improve engraftment and recovery of blood cells. This product complements Ayrmid’s commercial hematology portfolio, which includes Omisirge for hematologic malignancies and APHEXDA for autologous transplantation. Clinical studies supporting omidubicel show its ability to expand cell populations, enhance transplant outcomes, and address unmet needs in patients with severe aplastic anemia.

In May 2025, Cellenkos Inc., a US-based provider of therapy for aplastic anemia, formed a partnership with King Faisal Specialist Hospital & Research Centre in Riyadh to conduct clinical trials aimed at advancing global access to transformational cell therapies. The collaboration seeks to broaden Cellenkos’ international presence, speed up clinical validation, and deliver innovative treatments for rare diseases such as aplastic anemia and ALS. King Faisal Specialist Hospital & Research Centre, based in Saudi Arabia, offers advanced medical care and research services, with a focus on complex clinical trials and the treatment of rare diseases.

Major companies operating in the aplastic anemia market are Pfizer Inc., Johnson & Johnson Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceuticals Co. Ltd., UCB SA, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Cellenkos Inc., Amyndas Pharmaceuticals S.A., Hemogenyx Pharmaceuticals plc, Gamida Cell Ltd.

North America was the largest region in the aplastic anemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aplastic anemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aplastic anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the aplastic anemia market by increasing costs of imported immunosuppressive drugs, biologics, diagnostic reagents, and stem cell processing equipment used across hospital and specialty clinic settings. North America and Europe are most affected due to dependence on imported pharmaceuticals and advanced laboratory supplies, while Asia-Pacific faces pricing pressure on treatment accessibility. These tariffs are contributing to higher therapy costs and reimbursement challenges. However, they are also encouraging domestic pharmaceutical manufacturing, regional sourcing of medical supplies, and long-term investment in local biologics production capabilities.

The aplastic anemia market research report is one of a series of new reports that provides aplastic anemia market statistics, including aplastic anemia industry global market size, regional shares, competitors with a aplastic anemia market share, detailed aplastic anemia market segments, market trends and opportunities, and any further data you may need to thrive in the aplastic anemia industry. This aplastic anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Aplastic anemia is a rare condition in which the bone marrow is unable to generate sufficient blood cells, including red blood cells, white blood cells, and platelets. This lack can result in fatigue, recurrent infections, and increased bleeding or bruising. Treatment options may include medications that promote blood cell production or, in severe cases, bone marrow transplantation.

Aplastic anemia primarily occurs in two forms: acquired aplastic anemia and inherited bone marrow failure syndromes. Acquired aplastic anemia arises when the bone marrow is unable to generate adequate blood cells due to damage from external factors such as chemicals, drugs, or infections. Treatment options include bone marrow or stem cell transplantation, blood transfusions, and drug therapy, delivered through various routes including oral, parenteral, and others. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, catering to end users such as hospitals, home care settings, specialty clinics, and more.

The aplastic anemia market consists of revenues earned by entities by providing services such as supportive care for infections and monitoring and management of complications. The market value includes the value of related goods sold by the service provider or included within the service offering. The aplastic anemia market also includes sales of immunosuppressive medications and antibiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.